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Introduction

• We are investigating the effect of SSRIs and
other drugs on sign tracking – effective drugs
could be used in addiction treatment
• Sign tracking - the tendency of an organism
to approach and interact with the signal for
an appetitive stimulus. Contrast with goaltracking, approach of location of appetitive
stimulus (if separate from signal)
• Behavioral phenotype is determined by a
rat’s sign and goal tracking tendencies during
the training phase of the study
• Sign-tracking is relevant to addiction and
drug-seeking behaviors – recovering
addicts can be drawn to drug-related cues
that might cause relapse

Measured Behaviors
Sign tracking – lever presses
Goal tracking – food receptacle head entries
• We hypothesized a decrease in sign tracking
behaviors after administration of
Escitalopram

Sign-Tracking Totals

• Escitalopram is an SSRI used to treat
depression and anxiety disorders in humans
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Methods
• n = 31, Male Sprague-Dawley rats
• Habituation – 20 minutes per day for 2 days
• Introduced to banana pellets – day 2
• 48-hour break after session 2
• Training – 1 session per day for 5 days
• 25 trials per session
• Lever presented for 8 sec → banana
pellet drops in food receptacle
• Drug trials – injections were 48 hours apart
• Saline, 10mg/kg, or 20mg/kg
escitalopram– 30 min pre-trial
• Dose order was determined using a Latin
square design
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*NOTE: Lever-presses are not reinforced but used as measures of signtracking).

Results
• A mixed model ANOVA using dose and
behavioral phenotype as factors found a
significant effect of dose on sign tracking
probability, F(2, 56) = 28.98, p < .001, partial
2
h = .509, a significant effect of behavioral
phenotype on sign tracking probability, F(2,
28) = 25.1, p < .001, partial h2 = .642, and a
significant dose*behavioral phenotype
interaction, F(4, 56) = 8.95, p < .001, partial
2
h = .390.
• Post hoc testing with Tukey’s HSD found a
significant difference in total number of sign
tracking behaviors in sign trackers between
saline and 10mg dose, t(28) = 6.351, p <
.001, and between saline and 20mg dose,
t(28) = 8.165, p < .001.
• No other significant differences were found.

Discussion
• 10mg and 20mg doses of escitalopram
significantly reduced sign tracking behaviors
in sign trackers compared to saline
• Escitalopram could be an effective adjunctive
treatment for drug addiction, but human
studies need to be done to determine its
effectiveness in humans

